Specifications tableSubject areaGenomic medicineMore specific subject areaGenetic epidemiologyType of data*Tables.*How data was acquired*Smoking pattern survey, allelic discrimination assay by real-time PCR (Applied Biosystems, Foster City, CA, USA)*Data format*Filtered and analyzed.*Experimental factors*Peripheral blood sample, DNA extraction by BDtract DNA isolation kit (Maxim Biotech, Inc. San Francisco, California, USA).*Experimental features*Genotyping was performed using* 3 μL *of DNA at* 15 ng/μL *concentration and TaqMan probes (Applied Biosystems Foster City CA, USA). In each template, we included 3 non-template controls, and 1% of the samples were genotyped in duplicate as an allele assignment control.*Data source location*HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER) at México City*Data accessibility*Accessible from this article; DNA sample and raw data are available for further analyses in collaborative studies.***Value of the data**•Comparing and analyzing in other populations offer an opportunity to find causal genetic variants in tobacco smoking-related variables.•The analysis in mestizo smokers validates previous reports in Caucasian populations.•Further studies in other mestizo populations, with different degrees of Amerindian/Caucasian contribution, are desirables.

1. Data {#sec1}
=======

A descriptive table ([Table 1](#tbl1){ref-type="table"}) showing characteristics on the single nucleotide polymorphisms (SNPs) is included, these comprise gene location, alleles (change/minor), chromosome position, minor allele frequency and gene consequence when it applies.Table 1Characteristics in evaluated SNPs.Table 1GeneSNPAlleleChr PositionMAF[a](#tbl1fna){ref-type="table-fn"}Gene Consequence[b](#tbl1fnb){ref-type="table-fn"}ChangeMinor*CHRNA5*rs16969968G \> AA15:78590583A = 0.26553Missense Variant:D \[GAT\] \> N \[AAT\]rs17408276T \> CC15:78589276C = 0.2881Intron Variantrs680244C \> TC15:78578946T = 0.4098Intron Variant*CHRNA3*rs6495307C \> TT15:78597979T = 0.3994Intron Variantrs12914385C \> TT15:78606381T = 0.3138Intron Variant*NRXN1*rs10865246A/CC2:50443116C = 0.4950Intron Variantrs1882296T \> CC2:50039707C = 0.3900Intron Variantrs985919C \> AA2:50459875A = 0.4957Intron Variant*HTR2A*rs6311C \> TT13:46897343T = 0.39702KB Upstream Variantrs6313G \> AA13:46895805A = 0.40701Synonymous Variant: S \[TCC\] \> S \[TCT\][^2][^3]

Genotype frequencies for 10 SNPs in the candidate genes *CHRNA5* (rs16969968, rs17408276, rs680244), *CHRNA3* (rs6495307, rs12914385), *NRXN1* (rs10865246, rs1882296, rs985919) and *HTR2A* (rs6311, rs6313) were evaluated in the participation of smoking-related variables in Mexican Mestizo smokers and their characteristics are described in [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}.Table 2Genotype frequency of SNP in early and late smokers.Table 2GeneSNP/GenotypeES (n = 81)LS (n = 70)*CHRNA5*rs16969968nGF (%)nGF (%)GG4150.64463.8GA3441.92231.9AA67.434.3rs17408276TT4861.53855.9TC2937.22637.1CC11.345.7rs680244GG4758.04361.4GA2834.62332.9AA67.445.7*CHRNA3*rs6495307CC4658.24260.0CT3139.22332.9TT22.557.1rs12914385CC3543.24058.0CT3846.92637.7TT89.934.3*NRXN1*rs10865246AA3340.72738.6AC3745.73854.3CC1113.657.1rs1882296AA4251.93955.7AG3543.22637.1GG44.957.1rs985919TT2834.62434.3TG4758.03752.9GG67.4912.9*HTR2A*rs6311CC2632.12434.3CT3846.93955.7TT1721.0710.0rs6313GG5669.16085.7GA1417.357.1AA1113.657.1[^4]Table 3Genotype frequency of SNP in smoker status by cigarettes per day.Table 3GeneSNP/GenotypeHS (n = 86)MS (n = 11)LIS (n = 54)*CHRNA5*rs16969968nGF (%)nFG (%)nGF (%)GG4754.7763.63158.5GA3237.2436.42037.7AA78.100.023.8rs17408276TT4554.2550.03667.9TC3643.4440.01528.3CC22.4110.023.8rs680244GG4957.0763.63463.0GA3237.2327.31629.6AA55.819.147.4*CHRNA3*rs6495307CC4756.0654.53564.8CT3440.5436.41629.6TT33.619.135.6rs12914385CC3844.7763.63055.6CT3945.9436.42138.9TT89.400.035.6*NRXN1*rs10865246AA3338.4327.32444.4AC4451.2763.62444.4CC910.519.1611.1rs1882296AA4248.8654.53361.1AG3743.0436.42037.0GG78.119.111.9rs985919TT2731.4436.42138.9TG5058.1545.52953.7GG910.5218.247.4*HTR2A*rs6311CC2731.4436.41935.2CT4147.8763.62953.7TT1820.900.0611.1rs6313GG6980.211100.03666.7GA68.000.01324.1AA1112.800.059.2[^5]Table 4Genotype frequency of SNP in the level of nicotine dependence by FTCD.Table 4GeneSNP/GenotypesHD (n = 63)MD (n = 42)LD (n = 54)*CHRNA5*rs16969968nGF (%)nGF (%)nGF (%)GG3555.62661.92151.2GA2336.51535.71843.9AA57.912.424.9rs17408276TT3659.02561.02255.0TC2439.31536.61537.5CC11.612.437.5rs680244GG3352.43071.42354.8GA2844.41023.81331.0AA23.224.8614.3*CHRNA3*rs6495307CC3150.82866.72559.5CT2845.91331.01331.0TT23.312.449.5rs12914385CC3250.81945.22151.2CT2539.72047.61946.3TT69.537.112.4*NRXN1*rs10865246AA2844.41433.31638.1AC2946.02661.91945.2CC69.524.8716.7rs1882296AA3352.42559.52354.8AG2641.31433.31842.9GG46.337.112.4rs985919TT2539.71535.71126.2TG3250.82354.82764.3GG69.549.549.5*HTR2A*rs6311CC1930.21433.31740.5CT3250.82457.11945.2TT1219.049.5614.3rs6313GG4876.23173.83583.3GA711.1819.049.5AA812.737.137.1[^6]Table 5Genotype frequency of SNP according to COPD status.Table 5GeneSNP/GenotypesCOPD (n = 11)Non-COPD (n = 140)*CHRNA5*rs16969968nGF (%)nGF (%)GG545.58057.6GA545.55136.7AA19.185.8rs17408276TT327.38361.5TC872.74734.8CC00.053.7rs680244GG545.58560.7GA545.54632.9AA19.196.4*CHRNA3*rs6495307CC545.58360.1CT654.54834.8TT00.075.1rs12914385CC330.07251.4CT660.05841.4TT110.0107.1*NRXN1*rs10865246AA19.15942.1AC763.66848.6CC327.3139.3rs1882296AA218.27956.4AG763.65438.6GG218.275.0rs985919TT327.35035.7TG654.57855.7GG218.2128.6*HTR2A*rs6311CC981.84330.7CT00.07553.6TT218.12215.7rs6313GG1090.110675.7GA19.01812.9AA00.01611.4[^7]

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Participants {#sec2.1}
-----------------

Subjects with ≥30 years, men and women. To determine Mexican Mestizo ancestry, subjects were asked about their parents and grandparents ancestry and not belong to an indigenous group (See [Table 6](#tbl6){ref-type="table"}).Table 6Genotype frequency of SNP by therapy received.Table 6GeneSNP/GenotypesPT (n = 93)CBT (n = 47)*CHRNA5*rs16969968nGF (%)nGF (%)GG5155.42859.6GA3538.01736.2AA66.524.3rs17408276TT5158.02961.7TC3337.51736.2CC44.512.1rs680244GG5458.13063.8GA3032.31736.2AA99.700.0*CHRNA3*rs6495307CC5559.82860.9CT3133.71737.0TT66.512.2rs12914385CC4650.02348.9CT3841.32348.9TT88.712.1*NRXN1*rs10865246AA3537.62042.6AC4750.52246.8CC1111.8510.6rs1882296AA4750.52655.3AG4346.21634.0GG33.2510.6rs985919TT2931.21838.3TG5559.12451.1GG99.7510.6*HTR2A*rs6311CC2931.12042.5CT4548.42451.0TT1920.436.4rs6313GG6873.14187.2GA1314.036.4AA1212.236.4[^8]

Smokers recruited from the Smoking Cessation Support Clinic of the Department of Investigation in Tobacco Consumption and COPD at the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER) in Mexico City, with the following criteria: individuals who started smoking in adolescence (\<18 years) were defined as early smokers (ES) or those who started smoking in adulthood (≥18 years) defined as late smokers (LS); these subjects have been recruited previously in our research group [@bib2], [@bib3].

2.2. Smoking-related variables {#sec2.2}
------------------------------

A survey with smoking-related variables was assessed to daily smokers. They were asked about their smoking pattern by cigarette smoked per day (cpd), classified as heavy smokers (HS, ≥20 cpd), moderate smokers (MS, 11--19 cpd) and light smokers (LIS, ≤ 10 cpd). Level on nicotine dependence was measured by Fagerström Test for Cigarette Dependence (FCTD), classified as high (HD), moderate (MD) and low dependence (LD) by their score as 7 to 10, 5 and 6, and less than 4, respectively. According to the intervention received by the physicians and psychologists, individuals were classified as only cognitive-behavioral therapy (CBT) without any pharmacological therapy (PT), and CBT plus any PT, which could include nicotine replacement therapy and/or Bupropion and Varenicline.

2.3. COPD diagnosis {#sec2.3}
-------------------

As a requirement to attend the cessation sessions, participants were asked to perform spirometry in order to diagnose smoking-related diseases as chronic obstructive pulmonary disease (COPD). The diagnosis was done a physician and was based on patient medical history, physical examination, and spirometry data, with American Thoracic Society criteria. COPD was defined as an FEV1/FVC ratio of less than 70% in post-bronchodilator maneuver.

2.4. DNA extraction {#sec2.4}
-------------------

A 15 mL peripheral blood sample in tubes with EDTA was obtained from each participant through forearm venipuncture. The DNA extraction was performed using BDtract DNA isolation kit (Maxim Biotech, Inc. San Francisco, California, USA) and later was quantified by spectrophotometry with a NanoDrop 2000 (Thermo Scientific, DE, USA). DNA samples with a concentration \>100 ng/mL and purity with a 260/280 relation ≥2.

2.5. SNP selection {#sec2.5}
------------------

These 10 SNPs were selected because they were previously evaluated with cigarette smoking or with nicotine dependence in Mexican mestizo smokers [@bib1].

2.6. Genotyping {#sec2.6}
---------------

Genotyping was performed using a real-time PCR (7300 Real-Time PCR system, Applied Biosystems, Foster City, CA, USA) based allelic discrimination assay using 3 μL of DNA at 15 ng/μL concentration and TaqMan probes (Applied Biosystems Foster City CA, USA). In each template, were included 3 non-template controls, and 1% of the samples were genotyped in duplicate as an allele assignment control. Detection Software (SDS v. 1.4, Applied Biosystems). VIC™ and FAM™ dyes were used for alleles A and B, respectively.

2.7. Genotype frequency {#sec2.7}
-----------------------

All smokers in the study were compared by full genotype frequency according to the smoking-related variables.

Ethical approval {#sec3}
================

The protocol was approved by INER science and research bioethics and biosecurity committees (protocol number B15-16).

Transparency document {#appsec1}
=====================

The following is the transparency document related to this article:Multimedia component 1

Transparency document associated with this article can be found in the online version at [https://doi:10.1016/j.dib.2019.103893](https://doi:10.1016/j.dib.2019.103893){#intref0010}.

[^1]: These authors contributed equally.

[^2]: Minor allele frequency according to The genome Aggregation Database (gnomAD).

[^3]: Codon in brackets.

[^4]: ES: People who smoke cigarettes at an early age; LS: People who smoke cigarettes at a late age; GF: Genotype frequency.

[^5]: HS: People who were heavy smokers; MS: People who were moderate smokers; LIS: People who were light smokers; GF: Genotype frequency.

[^6]: HD: Smokers with high nicotine dependence; MD: Smokers with moderate nicotine dependence; LD: Smokers with low nicotine dependence; GF: Genotype frequency.

[^7]: COPD: Smokers with COPD; Non-COPD: Smokers without COPD; GF: Genotype frequency.

[^8]: PT: Smokers who received pharmacologic therapy and cognitive-behavioral therapy; CBT: Smokers who received only cognitive-behavioral therapy; GF: Genotype frequency.
